pCBh_NLS_hfCas13X(Cas13X_M17YY)_NLS-pA-U6-DR-BpiI-BpiI-DR-pSV40-EGFP-pA-pSV40-mCherry-pA Citations (2)

Originally described in: High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H, Huang J, Xiao Q, He B, Dong X, Liu Y, Yang X, Han D, Wang Z, Wang X, Ying W, Zhang R, Wei Y, Xu C, Zhou Y, Li Y, Cai M, Wang Q, Xue M, Li G, Fang K, Zhang H, Yang H Nat Biotechnol. 2022 Aug 11. pii: 10.1038/s41587-022-01419-7. doi: 10.1038/s41587-022-01419-7. PubMed Journal

---

Articles Citing pCBh_NLS_hfCas13X(Cas13X_M17YY)_NLS-pA-U6-DR-BpiI-BpiI-DR-pSV40-EGFP-pA-pSV40-mCherry-pA

Articles
Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. Chen S, Liu Z, Lo CH, Wang Q, Ning K, Zhang Q, Zhao J, Shen Y, Sun Y. PNAS Nexus. 2025 Jun 17;4(6):pgaf168. doi: 10.1093/pnasnexus/pgaf168. eCollection 2025 Jun. PubMed
Targeting Mettl14 Using an RNA-Targeting Clustered Regularly Interspaced Short Palindromic Repeat-High-Fidelity Cas13x System Attenuates Doxorubicin-Induced Cardiotoxicity. Wan W, Cui C, Zhou Y, Wang J, Zhao X, Cui X, Sun J, Yu P, Feng J, Wang T, Wang L, Xu J. J Am Heart Assoc. 2025 Aug 5;14(15):e040700. doi: 10.1161/JAHA.124.040700. Epub 2025 Jul 17. PubMed

If you have published an article using this material, please email us at to have your article added to this page.